A New Class of Anti-Malarial Agents Targetting Apical Membrane Antigen

一类针对顶膜抗原的新型抗疟疾药物

• 批准号: nhmrc : 1025150
• 负责人: Dr Sheena Mcgowan
• 金额: $ 39.85万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/new-class-anti-membrane-antigen/110412
• 关键词: New; Class; Anti; Malarial; Agents

Malaria is a major global health problem that imposes a substantial burden on the world’s most vulnerable societies. The invasion of host cells by malaria parasites represents an attractive target for therapeutic intervention, and Apical Membrane Antigen 1 (AMA1) plays an essential role in this process. Agents that bind to a key interaction site on AMA1 prevent host cell invasion and thus represent starting points for the development of a new class of anti-malarial drugs.

疟疾是一个重大的全球健康问题，给世界上最脆弱的社会带来了沉重的负担。疟疾寄生虫对宿主细胞的入侵是治疗干预的一个有吸引力的靶点，顶膜抗原1(AMA1)在这一过程中起着重要作用。与AMA1上的关键相互作用位点结合的药物可以防止宿主细胞入侵，从而代表着开发一类新的抗疟疾药物的起点。